Upregulation of transforming growth factor-b (TGF-b) signaling is interrelated with the development of airway remodeling. In this study, we examined the role of two E3 ubiquitin ligases, Arkadia and Smurf2, which are critically required for TGF-b signaling in airway remodeling. Rats were immunized with ovalbumin (OVA) and then challenged with an OVA aerosol. In in vitro experiments, normal human bronchial epithelial cells were stimulated with TGF-b 1 with or without the preincubation of Arkadia/Smurf2 small interfering RNA (siRNA) or lactacystin (an inhibitor of proteasomal degradation). In the lungs of OVA-treated rats, a large number of inflammatory cells were present near the airways. An increased subepithelial collagen deposition was associated with high expression levels of Smad7, SnoN and Ski mRNAs, Arkadia, Smurf2, and TGF-b type I receptor (TbRI), but low expression levels of Smad7, SnoN and Ski proteins. Smad7, SnoN and Ski interacted with both Arkadia and Smurf2 while TbRI only interacted with Smurf2 but not with Arkadia. In in vitro experiments, the inhibitory effect of TGF-b 1 on the expression of Smad7, SnoN and Ski was reversed by Arkadia siRNA and lactacystin, whereas the stimulatory effect of TGF-b 1 on the expression of TbRI protein and Smad7/SnoN/Ski mRNAs was not affected. In contrast, Smurf2 siRNA did not influence the effects of TGF-b 1 on the expression of the above proteins. Our results suggest that Arkadia may contribute to the pathogenesis of airway remodeling through enhancing TGF-b signaling by inducing the reduction of Smad7, SnoN and Ski proteins in OVA-sensitized and -challenged rats.
Asthma is a chronic inflammatory disease of the airways, and recurrent inflammation results in airway remodeling characterized by subepithelial fibrosis, myofibroblast and myocyte hyperplasia, together with epithelial damage, goblet cell metaplasia, edema and increased vascularity. 1 Transforming growth factor b (TGF-b), a fibrogenic cytokine, has been implicated in the development of airway remodeling in asthma on the basis of its strong capacity to induce the production of extracellular matrix factors including type 1 collagen (COL-I).
2 It is, therefore, possible that regulators of TGF-b activity might also have important role in the modulation of the airway remodeling process in asthma.
The process of TGF-b signaling pathway activation is known as follows. On TGF-b stimulation and activation of the TGF-b type I receptor (TbRI), R-Smads (Smad2 and Smad3) are phosphorylated. Then, phosphorylated R-Smads bind to Smad4, and are translocated into the nucleus, in which such a complex, together with additional DNA-binding co-factors, controls the transcription of TGF-b responsive genes. 3 In the process, negative regulators such as Smad7, SnoN and Ski can downregulate TGF-b signaling through multiple mechanisms. 3, 4 Accumulative evidence indicates that the expression of Smad7, SnoN and Ski proteins in some fibrotic models is obviously lower than that in the normal controls, [5] [6] [7] [8] [9] [10] [11] [12] [13] and also shows that upregulation of the expression of Smad7, SnoN or Ski proteins reverses or blocks fibrogenesis.
14-17 Nakao et al 18 reported that Smad7 immunoreactivity, which was present mainly in bronchial epithelial cells, was markedly decreased in asthmatic patients, compared with that of control subjects. However, the expression levels of SnoN and Ski in asthmatic patients are unclear.
The expression of Smad7, SnoN and Ski is modulated by the ubiquitin-proteasome degradation pathway, [19] [20] [21] and in the process of regulation, E3 ubiquitin ligases, such as Arkadia and Smurf2, induce ubiquitin-dependent degradation of Smad7, SnoN and Ski. [11] [12] [13] [19] [20] [21] [22] [23] Whereas Fukasawa et al 6, 13 reported that Smurf2 mediated the degradation of Smad7, SnoN and Ski in a mouse model of renal tubulointersitial fibrosis, Liu et al 7, 24 have shown that the reduction of Smad7 in a rat model of renal tubulointersitial fibrosis and normal human renal tubular epithelial cells may be mainly attributed to Arkadia, but not to Smurf2. Thus, how Arkadia and Smurf2 affect Smad7, SnoN and Ski in organ fibrosis remains to be clarified. Moreover, the interactions between Arkadia/Smurf2 and Smad7/SnoN/Ski in allergic airway remodeling are unknown. Therefore, this study was designed to clarify the effects of Arkadia and Smurf2 on the expression of Smad7, SnoN, Ski as well as TbRI in pathogenesis of airway remodeling in ovalbumin (OVA)-sensitized and -challenged rats in vivo and TGF-b 1 -treated bronchial epithelial cells in vitro.
MATERIALS AND METHODS Animals
All animals used in this study were 6-to 8-week-old male Sprague-Dawley rats obtained from the Experimental Animal Center of Central South University (Changsha, China). Animal study protocols were approved by the Animal Care Committee of Central South University and the experiments were carried out according to the guidelines of the committee.
Chronic Airway Remodeling Model
Eight rats were sensitized and challenged with OVA (OVAtreated group) to induce chronic airway remodeling. Briefly, the rats were immunized with an intraperitoneal injection of 100 mg of OVA (Sigma, St Louis, MO, USA), 200 mg of aluminum hydroxide (Sigma), and 6 Â 10 9 heat-killed Bordetella pertussis (Wuhan Institute of Biological Products, Wuhan, China) in 1 ml normal saline on days 0 and 14. From day 21, the rats were challenged for 30 min by nebulization of 1% (wt/vol) OVA in saline solution on 3 day/week for 6 weeks. As a control group, eight rats were sensitized with 1 ml normal saline and challenged with nebulized saline solution. All animals were killed 48 h after the final antigen or saline challenge.
Cell Culture and Treatment
Normal human bronchial epithelial cells (NHBECs) (Cell Center of Central South University, Changsha, China) were grown in a 5% CO 2 atmosphere at 37 1C in Dulbecco's modified Eagle's medium containing 10% fetal bovine serum in six-well plastic plates for 24 h, and then a recombinant human TGF-b 1 (R&D Systems, Minneapolis, MN, USA) at a final concentration of 5 ng/ml was added into the cell culture. The cells were collected 72 h later, and the expression of Arkadia, Smurf2, TbRI, Smad7, SnoN and Ski proteins and mRNAs in TGF-b 1 -stimulated NHBECs were detected by western blot and real-time RT-PCR, respectively. In an additional experiment, NHBECs were cultured with or without Arkadia, Smurf2 or control small interfering RNA (siRNA) (2 mg/ml, Sofarbio Technology, Hangzhou, China) for 24 h or lactacystin (10 mM, Sigma) for 3 h. Then, TGF-b 1 was added into the cell culture as described above. The cells were collected 72 h later, and the expression of Arkadia, Smurf2, TbRI, Smad7, SnoN and Ski proteins and mRNAs in TGFb 1 -stimulated NHBECs were detected as described above.
Histopathological Staining
Lung tissues were fixed in 4% paraformaldehyde in phosphate-buffered saline and embedded in paraffin. Tissue sections (4 mm thick) were stained with hematoxylin and eosin and Masson's trichrome for histopathological examination.
Western Blotting
The lung tissues and NHBECs were lysed with Nonidet P-40 (NP-40) lysis buffer as previously described. 7, 24 Proteins (20 mg) were loaded and separated by SDS-polyacrylamide gel electrophoresis (SDS-PAGE) and transferred to PolyScreen polyvinylidine difluoride transfer membranes (Pharmacia Corporation, Piscataway, NJ, USA). Immunoblotting was performed with different antibodies and visualized by the enhanced chemiluminescence (Amersham, Piscataway, NJ, USA) method. The primary antibodies purchased from Santa Cruz Biotechnology (Santa Cruz, CA, USA) were goat anti-Arkadia, goat anti-Smurf2, goat anti-SnoN, rabbit anti-Smad7, rabbit anti-Ski and rabbit anti-TbRI. Mouse monoclonal anti-b-actin (Sigma) was used as an internal control.
Immunoprecipitation
Each extract from lung tissues was incubated with 4 mg of specific anti-Smad7, anti-SnoN, anti-Ski or anti-TbRI antibody and 50 ml of protein G-Sephrose beads for 3 h at 4 1C. The immunoprecipitates were washed three times with cold lysis buffer and then separated by SDS-PAGE for immunoblotting of associated proteins in the complex. The lysates incubated with anti-rabbit IgG or anti-goat IgG, instead of the specific antibodies were used as negative controls.
Real-Time RT-PCR
Total RNA was extracted from the lung tissues and NHBECs by using Trizol (Invitrogen, Carlsbad, CA, USA). Reverse transcription of the RNA was performed by using a first-strand complementary DNA synthesis kit (Promega, Madison, MI, USA). The PCR with SYBR Green PCR Master Mix (Takara, Shiga, Japan) was used to analyze the mRNA expression of TGF-b 1 , COL-I, Smad7, SnoN and Ski. Realtime PCR was performed by using the ABI PRISM 7900-HT Sequence Detection System (Applied Biosystems, Foster City, CA, USA). The primer sequences used were as follows: rat
Realtime PCR data were analyzed according to the manufacturer's instructions.
Statistical Analysis
Data were presented as means ± s.d. The differences in the expression levels of proteins and mRNAs between control rats and OVA-treated rats were determined by the independent samples t-test. The differences in the expression levels of proteins and mRNAs among control NHBECs and NHBECs treated with TGF-b 1 , Arkadia siRNA, Smurf2 siR-NA, control siRNA and/or lactacystin were determined by one-way ANOVA with least significant difference as an adjusted post hoc test. All statistical analyses were performed using SPSS 11.0 (SPSS, Chicago, IL, USA). A P-value of o0.05 was considered statistically significant.
RESULTS

Histopathological Changes and the Expression of TGF-b 1 and COL-I in the Lungs of OVA-Treated Rats
A large numbers of inflammatory cells were present near the airways and there was a significant increase in the subepithelial collagen deposition in the lungs of OVA-treated rats, compared with those of control rats (Figure 1a) . These pathological changes were associated with a significant increase in TGF-b 1 and COL-I mRNAs expression in the lungs of OVA-treated rats, compared with those of control rats (Figure 1b) . The Interactions of Arkadia/Smurf2 with Smad7/SnoN/ Ski/TbRI in the Lungs of OVA-Treated Rats To determine the effects of Arkadia and Smurf2 on TGF-b signaling and airway remodeling, we analyzed the interactions of Arkadia/Smurf2 with Smad7, SnoN, Ski and TbRI in the lungs of OVA-treated rats using co-immunoprecipitation. In OVA-treated lungs, Arkadia-Smad7, Smurf2-Smad7, Arkadia-SnoN, Smurf2-SnoN, Arkadia-Ski and Smurf2-Ski complexes were all observed (Figures 4a-c) . In addition, the Smurf2-TbRI complex was observed; however, there was no complex composed of Arkadia and TbRI (Figure 4d ). These findings indicate that both Smurf2 and Arkadia interact with Smad7, SnoN and Ski, respectively, and Smurf2, but not Arkadia, interacts with TbRI in OVA-treated lungs. of TbRI in TGF-b 1 -stimulated NHBECs. In contrast to lactacystin, preincubation of Smurf2 siRNA or control siRNA did not reverse the low expression of Smad7, SnoN and Ski proteins in TGF-b 1 -stimulated NHBECs ( Figure 6 ).
Effects of Preincubation of
DISCUSSION
In this study, we showed that the lung of rats treated with OVA showed the progressive development of inflammatory infiltration and collagen deposition, which were associated Arkadia and airway remodeling X-Z Li et al with increased expression levels of TGF-b 1 , COL-I, Smad7, SnoN and Ski mRNAs, but simultaneous diminished levels of Smad7, SnoN and Ski proteins. We then found that the expression of Arkadia and Smurf2, which are known to induce ubiquitin-dependent degradation of Smad7, SnoN and Ski, was increased in OVA-treated lungs. Finally, we used coimmunoprecipitation, which showed that Smurf2 interacted with Smad7, SnoN, Ski and TbRI, and Arkadia only interacted with Smad7, SnoN and Ski, but not with TbRI. These findings suggest that there is little possibility of decreased translation of Smad7, SnoN and Ski proteins, and that Arkadia and Smurf2 may contribute to the reduction of these three proteins in the pathogenesis of allergic airway remodeling. Arkadia and Smurf2, two E3 ubiqutin ligases, have a pivotal role in regulating TGF-b signaling through selectively targeting key components of the Smad pathway for degradation. 11, 12, [20] [21] [22] [23] Smurf2 is known to induce the degradation of TGF-b receptors through interaction with Smad7, which enhances the inhibitory effect of Smad7 on TGF-b signaling. 19, 22 In addition, Lin et al 25 reported that Smurf2-regulated TGF-b signaling by potently reducing the transcriptional activity of Smad2. However, Bonni et al 23 have shown that Smurf2 may partner with phosphorylated Smad2 to enhance TGF-b signaling by degrading inhibitors such as SonN. When these findings are considered together, it seems that Smurf2 may exert bi-functional effects (ie, either amplify or inhibit) on the TGF-b signaling through partnership with different classes of signal proteins and regulatory factors. As shown by immunoprecipitation, Smurf2 interacted with TbRI in OVA-treated lungs. Previous studies have shown that Smurf2 induces the degradation of the TbRI protein and enhances the inhibitory effect of negative regulators on TGF-b signaling. 19, 22 These results and our findings seem to indicate that Smurf2 could result in the inhibition of TGF-b signaling in airway remodeling pathogenesis, which is contradictory to the notion that the upregulation of TGF-b signaling is crucial for the pathogenesis of airway remodeling. There, we showed that TbRI was increased in OVA-treated lungs. When these findings are considered together, it seems that Smurf2 is not competent to degrade the Smad7, SnoN and Ski in airway remodeling pathogenesis. Unlike Smurf2, Arkadia, which is widely expressed in embryonic and adult tissues, especially in lungs, is of relative specificity in modulation of TGF-b signaling. Arkadia interacts strongly with Smad6/7, SnoN and Ski, degrades these proteins, 20, 21 and specifically activates the transcription of TGF-b through Smad3/Smad4-binding sites and induces degradation of SnoN. 26 In addition, it is very important that Arkadia is not recruited to TGF-b receptors and does not degrade the receptors. 20 In other words, Arkadia regulates the transcriptional activity of TGF-b through degradation of Smad7, SnoN and Ski, but not TGF-b receptors. Therefore, Arkadia amplifies TGF-b signaling through degradation of Smad7, SnoN and Ski. 20, 21 Taken together, we presume that the reduction of Smad7, SnoN, and Ski could be mainly attributed to the high expression of Arkadia in allergic airway remodeling.
To confirm this presumption, we knocked down the expression of endogenous Arkadia and Smurf2 using siRNA in NHBECs. It was observed that there was a high level of TbRI expression with low levels of Smad7, SnoN and Ski expression in TGF-b 1 -stimulated NHBECs compared with control NHBECs. When NHBECs were preincubated with Arkadia siRNA and lactacystin, the reduction in the expression of Smad7, SnoN and Ski proteins induced by TGF-b 1 was partly reversed; however, the expression of TbRI protein and Smad7/SnoN/Ski mRNA were not affected. In contrast to Arkadia siRNA, Smurf2 siRNA had no influence on the expression of Smad7, SnoN and Ski proteins. Similar to Arkadia siRNA and lactacystin, Smurf2 siRNA also did not affect the expression of TbRI. In a previous study, Asano et al 27 have shown that the overexpression of Smurf2 and coexpression of Smad7 along with Smurf2 all did not affect the levels of TbRI protein in scleroderma fibroblasts. These findings, in agreement with ours, also suggest that Arkadiamediated positive regulation of TGF-b signaling may have a promoting role in allergic airway remodeling.
In conclusion, Arkadia may contribute to the pathogenesis of airway remodeling through enhancing TGF-b signaling by inducing the reduction of the expression of Smad7, SnoN and Ski proteins in OVA-sensitized and -challenged rats. Therefore, the identification of key molecular players such as Arkadia would be useful for therapeutic intervention in airway remodeling, and further investigation is required to determine the exact mechanisms.
